Amino Acid Catabolism Vaccines for Persistent Memory T-Cell Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines often induce short-lived effector responses rather than long-lived memory responses, leading to reduced protection over time, particularly in diseases like influenza and HIV, due to the tension between effector and memory cell differentiation pathways.
Innovation Solution
Incorporating nucleic acid sequences encoding enzymes of amino acid catabolic pathways, such as indoleamine 2,3-dioxygenase 1 (IDO1) and arginase 1 (ARG1), into vaccines to modulate immune responses, promoting the development of long-lived memory cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional vaccines are used to induce immune response, then effector cell production is achieved, but memory cell differentiation is inhibited and response duration is short
Solution Approach 1:
The patent introduces amino acid catabolic pathways (IDO1, ARG1, TDO) as intermediary mechanisms that modulate the immune response environment. These enzymes create metabolic conditions that mediate the transition from effector to memory cell differentiation, allowing both functions to coexist. The catabolic pathways act as intermediaries that consume amino acids to generate metabolites signaling memory cell fate.
Solution Approach 2:
The patent changes the metabolic parameters of the immune microenvironment by introducing amino acid catabolic enzymes. This alters amino acid availability and metabolite concentrations, which in turn changes the differentiation parameters of T cells from short-lived effector phenotype to long-lived memory phenotype, extending response duration.
2Duration of action of moving object
If amino acid catabolic pathways are introduced to promote memory cells, then memory response duration is extended, but effector cell production may be reduced
Solution Approach 1:
The vaccine design incorporates amino acid catabolic pathways that act preliminarily to shape the immune response trajectory. By establishing metabolic conditions early in the response that favor memory differentiation, the system prepares the environment in advance to sustain long-term immunity without compromising initial effector production.
Solution Approach 2:
The patent creates distinct phases in the immune response: an initial effector phase followed by a memory phase. The amino acid catabolic pathways are activated at specific time points to transition between these periodic phases, allowing effector cells to be produced first, then converted to or supported by memory cells in subsequent periods.
3Productivity
If inflammatory responses are promoted for effector differentiation, then effector cell production increases, but memory cell differentiation is inhibited
Solution Approach 1:
The patent converts the harmful effect of inflammatory responses (which inhibit memory differentiation) into a beneficial sequence. Inflammation is allowed to drive effector production first, then amino acid catabolic pathways are introduced to resolve inflammation and promote memory differentiation from the effector pool, turning the initial harmful effect into a beneficial two-stage process.
Solution Approach 2:
The immune response is made dynamic by introducing time-dependent regulation through amino acid catabolic pathways. The system transitions from an inflammatory state favoring effector cells to a resolved state favoring memory cells, with the catabolic pathways dynamically adjusting the metabolic environment to support different phases of the immune response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The strategy results in sustained, balanced immune responses with increased CD4+ T-cell activity and reduced IFNγ production, enhancing protection against diseases by fostering robust memory cell populations.
Implementation Method 1
Incorporating nucleic acid sequences encoding enzymes of amino acid catabolic pathways, such as indoleamine 2,3-dioxygenase 1 (IDO1) and arginase 1 (ARG1), into vaccines to modulate immune responses
Data Source
AI summary
Provided herein are recombinant polynucleotides including a first nucleic acid sequence encoding an antigen, and a second nucleic acid sequence encoding an enzyme of an amino acid catabolic pathway. The provided recombinant polynucleotides are particularly useful for inducing long-lived immune responses having improved memory characteristics. Also provided are pharmaceutical compositions, viral particles, and host cells including the disclosed recombinant polynucleotides, and methods for using the disclosed materials.